TYP - Tryptamine Theraputics

[Dona Ferentes]

I don't know what to think about this one. Not even a thread prior to this.

I came across this gush piece, but I don't understand the science, so over to the Collective Wisdom out there:

Exopharm's Big Idea Heading For A Big Business In EV Medicines

By Chris Baldwin

Big ideas can also become big businesses in biotech; the only difference is, they might not quite become household names.
Dr. Ian Dixon, an engineer and biotechnology entrepreneur, had a big idea back in 2013. Dixon was looking at regenerative medicine, and the promise of stem-cells. In particular, he was looking at the exosomes that stemcells secrete.
And this was his Eureka moment.

.... All cells produce exosomes, which are an essential component of cell to cell signalling: they are small particles that deliver therapeutic cargoes, such as protein and nucleic acids, to other cells to reduce inflammation and promote regeneration. Exosomes (also known as extra-cellular vesicles, or EVs) are plentiful in our youth but decline with age: one of the most important roles of exosomes is in slowing the ageing process.

Dixon realised that the exosomes released by stem cells could have a powerful rejuvenating effect on the cells that take them up. In fact, he realised that the EVs produced by stem cells could be a simpler product, and eclipse the use of stem cells as medicines, for many practical reasons....

full article found at:
https://www.sharecafe.com.au/2020/0...a-heading-for-a-big-business-in-ev-medicines/

Since inception daily

 

[Dona Ferentes]

has been in a TH for capital raising since last week

Readying for Phase 1 trials of Prospective, Randomised, Double Blind, placebo controlled, single dose, single site Phase I study to assess the safety and biological activity of a human nonautologous platelet derived Extracellular Vesicle therapy vs placebo on wound healing rate following skin punch biopsy in healthy volunteer adults.

 

[finicky]

Utterly smashed and has fallen into the clutches of a convertible note issuer on top of a savagely discounted renounceable rights issue priced at one (1) cent.
That's enough - I won't be seriously considering anything T Locantro promotes again. This one has been on his publicized faves list for a few years. He seems to blithely overlook the risk of hyper dilution for his money devouring spec picks. I almost took a nibble at this.

Not held

 

[System]

On May 6th, 2024, Exopharm Limited (EX1) changed its name and ASX code to Tryptamine Theraputics Limited (TYP).